ADC-1013 First-in-Human Study

Summary

The purpose of this study is to determine whether ADC-1013 (an agonistic human monoclonal IgG1 anti-CD40 antibody) is safe and tolerable when administered intratumorally (as repeated injections directly into the tumor tissue) or intravenously (as repeated doses directly into a vein) in patients with advanced solid tumors.

Timeline

Start

2015-04

Primary completion

2017-03-08

Completion

2017-03-08

Drugs

Indications